Precision Neuroscience’s Layer 7 Cortical Interface Gains FDA Breakthrough Approval

Precision Neuroscience has received 510(k) clearance from the United States Food and Drug Administration for its Layer 7 Cortical Interface. This device is a high-resolution cortical electrode array used in recording, monitoring, and stimulating electrical activity on the brain’s surface, for implant durations of up to 30 days.

This development marks a significant step forward for the BCI field, as it is the first full FDA clearance for a next-generation wireless BCI device. The approval allows Precision to begin offering its technology for clinical use, including procedures such as intraoperative brain mapping.

The Layer 7 Cortical Interface plays a central role in the company’s fully implantable, wireless BCI system, which remains under development. The approval means the device can now be used in patients for several weeks rather than just during surgery, enabling longer-term neural monitoring.

Longer implantation periods are expected to help Precision collect larger and more varied sets of neural data. This is seen as crucial to improving the performance of BCI systems, which rely on data to enhance the accuracy and effectiveness of their AI-driven decoding algorithms.

The cortical array is produced at the company’s own manufacturing site, reflecting its growing operational capabilities. The FDA clearance is viewed as a key milestone in Precision’s effort to bring meaningful BCI solutions to patients worldwide.